Blog - Page 1197 of 5708

ThursdaySep 30, 2021 12:40 pm

QualityStocksNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Simplifying Patients’ Lives with Easy Access to Point-of-Care Testing

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has remained committed to becoming the world’s largest health data company, as evidenced by its move to innovate and leverage specific point-of-care technologies within its community of pharmacies. It has also partnered with Abbott Canada, Shoppers Drug Mart and Ellerca Health in a bid to facilitate its growth and make its technology and services accessible to as many people as possible. “Avricore’s flagship platform, HealthTab(TM), impacts the healthcare sector mainly by simplifying patients’ lives with easy access to point-of-care testing,” reads a recent article. “With HealthTab, Avricore can offer pharmacies complete turnkey and point-of-care…

ThursdaySep 30, 2021 12:05 pm

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Offers Innovative, Practical Solution for Green Hydrogen

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is making the green hydrogen economy possible through its proprietary carbon-free ammonia (“NH3”) system. “The hydrogen economy envisions a future where carbon-free hydrogen is used for energy storage, long-distance transportation of energy, and as a fuel for vehicles and heat generation,” reads a recent article. Although hydrogen, as a fuel, burns cleanly and produces more power per unit weight than gasoline, diesel or even lithium-ion batteries, there are practical problems that have so far prevented the implementation of the hydrogen economy. Firstly, blue and grey hydrogen production using the traditional methods is energy intensive and…

ThursdaySep 30, 2021 11:57 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Commences Trading on the OTCQX Best Market

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that it has graduated from the OTCQB Venture Market to now trade on the OTCQX Best Market, the highest tier of OTC Markets Group. “Receiving approval to trade on the OTCQX is an important milestone for MINDCURE, validating the outstanding efforts of our entire team to build a leading psychedelics company and to drive value for patients, therapists, clinics and shareholders,” said Kelsey Ramsden, president and chief executive officer of MINDCURE. “Trading on the OTCQX Market enhances the…

ThursdaySep 30, 2021 11:36 am

QualityStocksNewsBreaks – DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Releases Q2 2022 Financial Results, Corporate Update

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, is reporting its financial results for both the three-month and six-month period ended on July 31, 2021. Worth noting is the announcement that the company saw unrealized gain on digital currencies for the period of C$2.65 million while net equity in the company reached C$17.39 million in Q1 2022 and a further C$1.9 million in Q2 2022. Since unrealized digital currency gains are not included in the net income/loss report under IFRS but are recognized under comprehensive loss, revenues for the six months ended…

ThursdaySep 30, 2021 11:14 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as…

ThursdaySep 30, 2021 10:56 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803 During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical…

ThursdaySep 30, 2021 10:44 am

Communications Tech and Data Services Provider FingerMotion Inc. (FNGR) Building Strong IP in China’s Large Insurance Market

FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers The Sapientus platform creates proprietary matrices for assessing consumer risk potential…

ThursdaySep 30, 2021 10:23 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, further patient enrollment, randomization and dosing is currently underway as well as a robust lineup of globally located clinical sites, which are advancing toward activation and enrollment. “As one of the most aggressive, deadly and treatment-resistant cancers that…

ThursdaySep 30, 2021 10:18 am

Friendable Inc. (FDBL) Changing How Musical Artists Earn Revenue in an Industry That Is Constantly Changing

Some social media platforms, like TikTok, pay artists for their music, but the amounts are insignificant, and an artist's musical track would have to be used hundreds of thousands of times to make a decent profit Friendable’s Fan Pass Live provides artists an online platform to share their music content and earn a profit Artists earn on Fan Pass through fan subscriptions, merchandise sales, ticket sales, and more Fan Pass artists have access to Pro Services that include logo design and merchandise, as well as social media promotions for upcoming events 2020 was a year of change (and growth) for…

ThursdaySep 30, 2021 9:49 am

QualityStocksNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Releases Pricing of Proposed Public Offering

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, has announced an underwritten public offering of 4,700,000 shares of its common stock and accompanying warrants. According to the announcement, the pricing of the public offering, which included each share of common stock being sold together with 0.75 warrants for a combined price of $1.70, is $8 million before deducting typical underwriting discounts and offering expenses. The company anticipates using net proceeds from the offering to fund working capital and general corporate purposes. KAVL anticipates granting the underwriters a 45-day option to purchase up to an…

Site Search

Company Search